A striking statistical finding has emerged from recent clinical trial data: GlaxoSmithKline’s experimental hepatitis B treatment bepirovirsen achieved functional cure in 18% of patients—an 18-fold improvement compared to the 1% cure rate observed with current standard therapies.
This substantial disparity underscores the critical need for novel therapeutic approaches in hepatitis B management. The drug works through an innovative antisense RNA mechanism that differs fundamentally from existing nucleoside analogue treatments, targeting viral replication at the molecular level rather than merely suppressing viral activity.
Given that approximately 296 million people globally live with chronic hepatitis B, and the condition remains a leading cause of liver cirrhosis and hepatocellular carcinoma, these results carry significant public health implications. Phase 3 clinical trials are expected to commence within the coming year, potentially accelerating the path toward regulatory approval and broader patient access.
Read the full article on GMJ Newsroom.
Was this article helpful?
